Marshall Health
Marshall Health
Huntington, West Virginia, United States6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Chemically-Induced Disorders, Digestive System Diseases, alcohol-induced disorders, alcohol-related disorders, alcoholic hepatitis, alcoholic liver disease, hepatitis, liver disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07428538 | |
| Responding With Evidence and Access for Childhood Headaches | Headache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, migraine with aura, migraine without aura, nervous system disorder | Recruiting | Not applicable | 2026-09-21 | NCT05889624 | |
| DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Hypoxia, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Respiratory, cardiovascular disorder, hypertensive disorder, interstitial lung disease, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Recruiting | Not stated | 2026-08-26 | NCT06388421 | |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Narcotic-Related Disorders, Neoplasms by Histologic Type, Opioid Use Disorder, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-08-11 | NCT06651177 | |
| Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids | Opioid Withdrawal (Disorder) | Active, not recruiting | Phase 2 | 2025-10-01 | NCT06047834 | |
| Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Active, not recruiting | Not applicable | 2025-05-23 | NCT02336217 |